Literature DB >> 34135317

VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway.

Ying Tong1, Jinyan Kai1,2, Shuo Wang3, Yiwen Yu1, Suhong Xie1, Hui Zheng1, Yanchun Wang1, Yixuan Liu1,2, Keyu Zhu1,2, Xiaolin Guan1,2, Lin Guo4,5, Renquan Lu6,7.   

Abstract

Clear cell renal cell carcinomas (ccRCC) reprogram carbon metabolism responses to hypoxia, thereby promoting utilization of glutamine. Recently, sirtuin 4 (SIRT4), a novel molecular has turned out to be related to alternating glutamine metabolism and modulating the tumor microenvironment. However, the role of SIRT4 in ccRCC remains poorly understood. Here, we illustrated that the expression of SIRT4 is markedly reduced in cancerous tissues, and closely associated with malignancy stage, grade, and prognosis. In ccRCC cells, SIRT4 exerted its proapoptotic activity through enhancing intracellular reactive oxygen species (ROS). Heme oxygenase-1 (HO-1) is part of an endogenous defense system against oxidative stress. Nevertheless, overexpression of SIRT4 hindered the upregulation of HO-1 in von Hippel-Lindau (VHL)-proficient cells and repressed its expression in VHL-deficient cells. This discrepancy indicated that competent VHL withstands the inhibitory role of SIRT4 on HIF-1α/HO-1. Functionally, overexpression of HO-1 counteracted the promotional effects of SIRT4 on ROS accumulation and apoptosis. Mechanistically, SIRT4 modulates ROS and HO-1 expression via accommodating p38-MAPK phosphorylation. By contrast, downregulation of p38-MAPK by SB203580 decreased intracellular ROS level and enhanced the expression of HO-1. Collectively, this work revealed a potential role for SIRT4 in the stimulation of ROS and the modulation of apoptosis. SIRT4/HO-1 may act as a potential therapeutic target, especially in VHL-deficient ccRCCs.

Entities:  

Year:  2021        PMID: 34135317     DOI: 10.1038/s41419-021-03901-7

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  49 in total

1.  Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer.

Authors:  Assaf Magen; Avinash Das Sahu; Joo Sang Lee; Mahfuza Sharmin; Alexander Lugo; J Silvio Gutkind; Alejandro A Schäffer; Eytan Ruppin; Sridhar Hannenhalli
Journal:  Cell Rep       Date:  2019-07-23       Impact factor: 9.423

2.  SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells.

Authors:  Marcia C Haigis; Raul Mostoslavsky; Kevin M Haigis; Kamau Fahie; Danos C Christodoulou; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Margaret Karow; Gil Blander; Cynthia Wolberger; Tomas A Prolla; Richard Weindruch; Frederick W Alt; Leonard Guarente
Journal:  Cell       Date:  2006-09-08       Impact factor: 41.582

3.  UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer.

Authors:  Qiangsheng Hu; Yi Qin; Shunrong Ji; Wenyan Xu; Wensheng Liu; Qiqing Sun; Zheng Zhang; Mengqi Liu; Quanxing Ni; Xianjun Yu; Xiaowu Xu
Journal:  Cancer Lett       Date:  2019-03-22       Impact factor: 8.679

Review 4.  Glutaminolysis: A Hallmark of Cancer Metabolism.

Authors:  Lifeng Yang; Sriram Venneti; Deepak Nagrath
Journal:  Annu Rev Biomed Eng       Date:  2017-03-08       Impact factor: 9.590

5.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Authors:  Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

Review 6.  The Role of Sirtuins in Antioxidant and Redox Signaling.

Authors:  Chandra K Singh; Gagan Chhabra; Mary Ann Ndiaye; Liz Mariely Garcia-Peterson; Nicholas J Mack; Nihal Ahmad
Journal:  Antioxid Redox Signal       Date:  2017-10-20       Impact factor: 8.401

7.  The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4.

Authors:  Alfred Csibi; Sarah-Maria Fendt; Chenggang Li; George Poulogiannis; Andrew Y Choo; Douglas J Chapski; Seung Min Jeong; Jamie M Dempsey; Andrey Parkhitko; Tasha Morrison; Elizabeth P Henske; Marcia C Haigis; Lewis C Cantley; Gregory Stephanopoulos; Jane Yu; John Blenis
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

Review 8.  SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis.

Authors:  Yueming Zhu; Yufan Yan; Daniel R Principe; Xianghui Zou; Athanassios Vassilopoulos; David Gius
Journal:  Cancer Metab       Date:  2014-10-20

Review 9.  Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.

Authors:  Yongchang Lai; Zhijian Zhao; Tao Zeng; Xiongfa Liang; Dong Chen; Xiaolu Duan; Guohua Zeng; Wenqi Wu
Journal:  Cancer Cell Int       Date:  2018-03-05       Impact factor: 5.722

10.  Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways.

Authors:  Norma Masson; Peter J Ratcliffe
Journal:  Cancer Metab       Date:  2014-02-04
View more
  3 in total

Review 1.  Association between HO‑1 gene promoter polymorphisms and diseases (Review).

Authors:  Lin-Lin Ma; Lei Sun; Yu-Xi Wang; Bai-He Sun; Yan-Fei Li; Yue-Ling Jin
Journal:  Mol Med Rep       Date:  2021-11-29       Impact factor: 2.952

Review 2.  Mechanism research and treatment progress of NAD pathway related molecules in tumor immune microenvironment.

Authors:  QinChen Xu; Xiaoyan Liu; Ghazal Mohseni; Xiaodong Hao; Yidan Ren; Yiwei Xu; Huiru Gao; Qin Wang; Yunshan Wang
Journal:  Cancer Cell Int       Date:  2022-07-30       Impact factor: 6.429

Review 3.  Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma.

Authors:  Huijie Zhang; Lei Yu; Jing Chen; Liting Liu; Xudong Yang; Hongwei Cui; Genquan Yue
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.